Antisecretory Factor Protein Normalizes Tumor Pressure for Drug Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in delivering anticancer drugs effectively to tumor tissues due to barriers such as heterogeneous blood supply, elevated interstitial pressure, and uneven drug distribution, leading to inadequate drug uptake and resistance to therapy.
Innovation Solution
The use of antisecretory factor (AF) protein or its derivatives to regulate the Na+—K+-2Cl− co-transporter (NKCC1) by interacting with CAP/ponsin and FAK, thereby normalizing intracellular and interstitial pressures, enhancing the uptake of pharmaceutical substances into cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cancer treatments are used, then treatment is administered, but drug uptake is inadequate due to elevated interstitial pressure and heterogeneous blood supply
Solution Approach 1:
The patent applies parameter changes by modifying the physiological state of tumor cells through AF treatment, which normalizes ion channel activity and reduces intracellular and interstitial pressure. This parameter change (pressure reduction) directly addresses the barrier to drug uptake, enabling better drug delivery without changing the drug itself
Solution Approach 2:
The antisecretory factor (AF) serves as an intermediary substance that mediates between the treatment system and the tumor tissue. AF interacts with CAP/ponsin and FAK to regulate NKCC1, thereby indirectly facilitating drug uptake by normalizing pressure conditions. This intermediary approach allows the system to overcome the pressure barrier without direct mechanical intervention
2Quantity of substance
If higher drug doses are administered to overcome poor uptake, then drug availability increases, but side effects increase and therapeutic window narrows
Solution Approach 1:
The patent applies preliminary action by administering AF before the anticancer drug to normalize tumor cell pressure and improve uptake conditions. This preparatory step ensures that when the drug is subsequently administered, it can be effectively taken up at lower doses, thereby reducing side effects while maintaining therapeutic efficacy
Solution Approach 2:
AF acts as a mediator that improves the relationship between drug dosage and therapeutic outcome. By normalizing pressure parameters, AF enables lower drug doses to achieve the same therapeutic effect, thus reducing harmful side effects while maintaining adequate drug availability at the target site
3Quantity of substance
If AF is used to normalize ion channel activity, then cellular uptake is improved, but treatment complexity increases
Solution Approach 1:
The patent uses AF as a biochemical intermediary that naturally interacts with existing cellular components (CAP/ponsin, FAK, NKCC1) to achieve pressure normalization. This approach leverages endogenous pathways rather than introducing complex external systems, thereby improving cellular uptake while keeping treatment complexity relatively low
Solution Approach 2:
The treatment approach enables the tumor cells to self-regulate their pressure conditions through AF-mediated interaction with their own ion channels and signaling proteins. The cells' existing molecular machinery (NKCC1, FAK, CAP) is harnessed to achieve normalization, reducing the need for complex external intervention systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AF proteins facilitate improved cellular uptake of drugs by normalizing ion channel activity in pathological cells, potentially reducing drug dosage and minimizing side effects while enhancing therapeutic efficacy.
Implementation Method 1
AF can intervene in the biological activation of transmembrane proteins, such as Na+—K+-2Cl− co-transporter (NKCC1), by interacting with CAP/ponsin (c-Cbl associated protein) and FAK (focal adhesion kinase)
Data Source
AI summary
The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.